MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI) announced that it will hold a conference call at noon Eastern time today to discuss the label change for Fareston® (toremifene citrate) 60 mg announced on January 22nd by the European Medicines Agency (EMEA) recommending that Fareston not be used in patients at risk of prolonged QT interval, as well as the results of a Thorough QT/QTc study of toremifene conducted by GTx, and GTx’s views as to the implications of the results of this study on its toremifene product candidates.
